Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of Dabigatran Etexilate with/without Ranitidine
NCT02170792Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Feb 2001
- Primary completion
- Mar 2001
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, open-label trial of dabigatran in thromboembolism (2 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Area under the plasma drug concentration curve for BIBR 953 ZW from 0 to 12 hours and Area under the plasma drug concentration time curve of BIBR 953 ZW within the interval from zero time to tf. Started Feb 2001; status: completed.
02
Drugs
dabigatran
03
Conditions
thromboembolism
Beyond the preview
Go deeper on NCT02170792.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02170792.